NCT05132582: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Tyrosine-Kinase Inhibitor, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have received 4-8 cycles (21 day cycles) of previous treatment with Herceptin/trastuzumab, Perjeta/pertuzumab, and taxane as first-line therapy for advanced HER2+ breast cancer with no evidence of disease progression
Exclusions: Patients with symptomatic brain metastases that require treatment – see trial for details; Patients with known or suspected leptomeningeal disease (LMD); Patients with prior treatment with any anti-HER2 and/or anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (e.g. pyrotinib, Tykerb/lapatinib, Tukysa/tucatinib, Nerlynx/neratinib)

Comments are closed.

Up ↑